Indaptus Therapeutics, Inc.
INDP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $7 | $8 | $6 | $3 |
| G&A Expenses | $8 | $9 | $9 | $5 |
| SG&A Expenses | $8 | $9 | $9 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $15 | $16 | $15 | $8 |
| Operating Income | -$15 | -$16 | -$15 | -$8 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $1 | $1 | $0 |
| Pre-Tax Income | -$15 | -$15 | -$14 | -$8 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$15 | -$15 | -$14 | -$8 |
| % Margin | – | – | – | – |
| EPS | -1.61 | -1.84 | -1.73 | -1.89 |
| % Growth | 12.5% | -6.4% | 8.5% | – |
| EPS Diluted | -1.61 | -1.84 | -1.73 | -1.89 |
| Weighted Avg Shares Out | 9 | 8 | 8 | 4 |
| Weighted Avg Shares Out Dil | 9 | 8 | 8 | 4 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $1 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$15 | -$16 | -$15 | -$8 |
| % Margin | – | – | – | – |